BeOne Medicines (ONC) Net Income towards Common Stockholders (2015 - 2026)

BeOne Medicines (ONC) has reported Net Income towards Common Stockholders for 12 consecutive years, with $227.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 17802.13% year-over-year to $227.4 million; the TTM figure through Mar 2026 stood at $513.0 million (up 230.75% YoY), while the FY2025 annual figure was $286.9 million, up 144.5% from the prior year.
• Net Income towards Common Stockholders climbed to $227.4 million in Q1 2026 per ONC's latest filing, from $66.5 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $227.4 million in Q1 2026 and bottomed at -$565.7 million in Q2 2022.
• Historically, Net Income towards Common Stockholders has averaged -$177.4 million across 5 years, with a median of -$151.9 million in 2024.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 754.48% — and 2026, when it surged 17802.13%.
• BeOne Medicines' Net Income towards Common Stockholders stood at -$445.3 million in 2022, then climbed by 17.47% to -$367.6 million in 2023, then surged by 58.68% to -$151.9 million in 2024, then surged by 143.79% to $66.5 million in 2025, then soared by 241.88% to $227.4 million in 2026.
• Business Quant data shows ONC's Net Income towards Common Stockholders at $227.4 million in Q1 2026, $66.5 million in Q4 2025, and $124.8 million in Q3 2025.